Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to help picky eaters with ARFID expand their diet

NCT ID NCT07385469

Symptom relief Sponsor: Hacettepe University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two therapy approaches to help children aged 3-8 with Avoidant/Restrictive Food Intake Disorder (ARFID) eat more foods and have less stressful mealtimes. One group gets a sensory-based feeding program, another adds coaching for parents, and a third group gets standard care. The goal is to see which approach works best for improving eating habits and reducing mealtime battles.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 to 8 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion Criteria (for the child): * Having been diagnosed with ARFID according to the DSM-5 by a Child and Adolescent Mental Health and Diseases psychiatrist (Assoc. Prof. Dr. Hakan ÖĞÜTLÜ). * Being between the ages of 3 and 8. * Being medically stable for outpatient treatment. * Having no conditions (visual, auditory, cognitive, or chewing) that would prevent participation in treatment. Inclusion Criteria (for the mother): * Being the child's primary caregiver and living with the mother. * Having at least a primary school diploma and possessing Turkish reading and comprehension proficiency. * Agreeing to take an active role in the intervention process and participate in research evaluations. * Being a regular participant in the child's feeding process. * Not having another child with special needs. Exclusion Criteria: * Exclusion Criteria (Child): * History of comorbid neurological, genetic, psychiatric, or metabolic disease * Child and family receiving other individual or family-based education and/or psychotherapy during the intervention * Taking medication for comorbid disorders affecting appetite and/or weight * Active psychiatric crisis (e.g., severe anxiety disorder, post-traumatic stress disorder) * Significant family or environmental constraints that would prevent regular attendance Exclusion Criteria (Mother): * Severe hearing, vision, or cognitive impairment * Child concurrent participation in another intervention program (dietician, psychotherapy, group education, etc.) related to feeding behaviors * Presence of a chronic health condition (e.g., neurological, psychiatric, orthopedic, oncological, etc.) that would prevent regular attendance at the intervention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARFID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

avoidant/restrictive food intake disorder Feeding and Eating Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARFID

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hacettepe University, Department of Occupational Therapy, Pediatric Unit

    Ankara, Altındağ, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.